Composition capable of decreasing uric acid and preparation thereof
A technology for reducing uric acid and composition, applied in the field of uric acid-lowering compositions and preparations thereof, can solve problems such as neutropenia, patient suffering, threat to health, etc., and achieve the effects of promoting uric acid excretion, good uric acid-lowering effect, and lowering uric acid value
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0044] Embodiment 1 uric acid lowering test
[0045] 1. Materials and methods
[0046] Experimental animals: SPF grade male SD rats, weighing 180±10 g, were provided by Beijing Speiford Experimental Animal Center (permit number: SYXK (Beijing) 2014-0037).
[0047] Test groups: The test is divided into blank control group, model group, benzbromarone control group, first control group, second control group and test group, with 10 rats in each group.
[0048] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 1.5ml / 100g. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.
[0049] Drug preparation: ready-to-use and ready-to-use, weigh a certain amount of the test substance, add an appropriate amo...
Embodiment 2
[0073] Embodiment 2 lowering uric acid test
[0074] 1. Materials and methods
[0075] Experimental animals: male SD rats with SPF grade, weighing 180±10g, provided by Beijing Speiford Experimental Animal Center, (permit number: SYXK (Beijing) 2014-0037)
[0076] Test groups: The test is divided into blank control group, model group, benzbromarone control group, first control group, second control group and test group, with 10 rats in each group.
[0077] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 1.5ml / 100g. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.
[0078] Drug preparation: ready-to-use and ready-to-use, weigh a certain amount of the test substance, add an appropriate amou...
Embodiment 3
[0102] Embodiment 3 lowering uric acid test
[0103] 1. Materials and methods
[0104] Experimental animals: male SD rats with SPF grade, weighing 180±10g, provided by Beijing Speiford Experimental Animal Center, (permit number: SYXK (Beijing) 2014-0037)
[0105] Test groups: The test is divided into blank control group, model group, benzbromarone control group, first control group, second control group and test group, with 10 rats in each group.
[0106] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 1.5ml / 100g. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.
[0107] Drug preparation: ready-to-use and ready-to-use, weigh a certain amount of the test substance, add an appropriate amou...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com